Overview

CAR T-cell Therapy in Patients With Renal Dysfunction

Status:
Not yet recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Northside Hospital, Inc.
Collaborator:
Blood and Marrow Transplant Group of Georgia
Treatments:
Cyclophosphamide
Fludarabine